Aptevo Therapeutics Inc. (NASDAQ: APVO) entered into a $60 million equity line of credit with Yorkville Advisors Global, LP, effective January 8, 2026. The facility was announced on January 9, 2026 and provides the company with a flexible source of capital that can be drawn at its discretion under market‑based terms.
The ELOC is priced at 96 % of the lowest volume‑weighted average price over a three‑day period, with no warrants attached. Shareholder approval is required to access the full $60 million capacity, but the company can draw on the line without immediate dilution. The terms include minimal fees and a cap on the number of shares that can be sold in any 12‑month period, giving Aptevo control over the timing and amount of capital raised.
The financing extends Aptevo’s funding runway into 2029, a critical milestone for a clinical‑stage biopharma that has no product revenue and a high cash burn rate. The line will support the ADAPTIR® and ADAPTIR‑FLEX® platform programs, including the lead bispecific antibody mipletamig, and will allow the company to continue clinical development and pre‑clinical work without the need for an immediate equity raise. Prior to the ELOC, Aptevo had completed a 1‑for‑18 reverse stock split effective December 29, 2025 and a 1‑for‑44 split effective March 5, 2024, actions taken to maintain Nasdaq bid‑price compliance and reduce share count.
CFO Daphne Taylor said the agreement “offers added flexibility and control over how and when we access capital. Importantly, the fully leveraged facility plus cash on hand is sufficient to fund us for three years, into 2029.” CEO Marvin White added that the company remains confident in its CD3‑based bispecific approach and its ability to balance potent immune activation with safety.
The announcement was met with a 10.4 % pre‑market rise in the company’s shares, reflecting investor confidence that the extended runway and the ability to raise capital without immediate dilution will support the company’s pipeline and potential strategic partnerships. The market reaction was driven by the combination of a sizable, low‑cost financing source, minimal fees, and the absence of warrants, all of which reduce dilution risk while providing the capital needed to advance the ADAPTIR platform.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.